Ribhi Shawar | Branch Chief, Division of Microbiology
CDRH OIVD FDA

Ribhi Shawar, Branch Chief, Division of Microbiology, CDRH OIVD FDA

Dr. Ribhi Shawar currently serves as the Branch Chief at the Division of Microbiology in the Office of In vitro Diagnostic and Radiological Health (OIR) at the Center for Devices and Radiological Health (CDRH) at FDA where he specializes in the area of antimicrobial susceptibility testing and detection of resistance. Dr. Shawar has a Ph.D. in Medical Microbiology and an M.Sc. in Medical Parasitology. He is a certified diplomate by the American Board of Medical Microbiology (ABMM) for 25 years. Dr. Shawar is a recognized clinical microbiologist with diverse experience in hospital settings, diagnostic and pharmaceutical microbiology and anti-infective drug development with strong knowledge in regulatory aspects both in antimicrobial drug products and infectious disease diagnostics. Dr. Shawar has authored multiple publications in peer reviewed journals, served or currently serves as advisor to several CLSI Sub-committees and is the recipient of multiple awards including GSK Gold Award. He served for two terms as Chair of the ABMM Standards and Examinations Committee (Parasitology) and as member of the editorial board of the Journal of Clinical Microbiology. Prior to joining FDA, Dr. Shawar served in multiple roles at various institutions including Baylor College of Medicine, VA Medical Center in Houston, PathoGenesis Corporation, Chiron (Novartis) in Seattle, and GlaxoSmithKline in Philadelphia.

Appearances:



World Anti-Microbial Resistance Congress USA 2018 - Day 2 @ 11:10

Update on FDA guidance for the coordinated development of antimicrobial drugs and antimicrobial susceptibility test devices

  • Importance of coordinated development for both drug and device manufacturers
  • What has happened in the past year after the guideline implementation for AST
  • How are providers taking advantage of new developments to decrease time to approval and market
last published: 18/Oct/18 13:55 GMT

back to speakers